---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39796229.md"
description: "WuXi AppTec's leading position in CRO is solid, but it continues to be suppressed by the legislative risks of the U.S. "Biosecurity Act," with its valuation remaining in a historically low range for an extended period.Hengrui Medicine has passed through the difficult period of its transformation into an innovative drug company in mainland China, with multiple pipeline products reaching key clinical milestones, and its GLP-1 layout is also accelerating.RemeGen has clear competitiveness in the antibody-drug conjugate (ADC) field, and the overseas licensing progress of products like RC48 is a core catalyst.Deshi is a promising newcomer in the gene and cell therapy sector on the Hong Kong stock market, early-stage but with high growth potential.Hong Kong's biopharmaceutical sector has been suppressed by geopolitical and regulatory risks this year, but frequent M&A activities suggest that global pharmaceutical giants have started bargain hunting, indicating clear bottom valuation characteristics."
datetime: "2026-04-09T09:45:51.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39796229.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39796229.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39796229.md)
author: "[quant_notes](https://longbridge.com/en/profiles/26648922.md)"
---

# WuXi AppTec's leading position in CRO is solid, bu…


### Related Stocks

- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [02526.HK](https://longbridge.com/en/quote/02526.HK.md)
- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)